# Variant Analysis Report #6

**Gene:** FBN1

**Variant:** NM_000138.5:c.6446A>C

---

<think>
Okay, let's tackle this variant interpretation for FBN1 c.6446A>C. First, I need to recall the ACMG/AMP 2015 guidelines and the ClinGen SVI recommendations. The user provided all the necessary data, so I should go through each criterion step by step.

Starting with PVS1: This is for variants in a gene where the variant is a null (nonsense, frameshift, canonical splice site, etc.) and the disease is caused by loss of function. The variant here is a missense (p.Tyr2149Ser), so PVS1 doesn't apply. No evidence here.

Next, PS1-4. PS1 is for a variant in a gene where the variant is a known pathogenic variant in the same gene. But ClinVar and HGMD don't have this variant listed, so PS1 is not met. PS2 is for a variant that has been reported in multiple unrelated individuals with the disease. No data on that here. PS3 is for a variant that has a high likelihood of being pathogenic based on functional studies. But the functional studies are N/A, so PS3 isn't met. PS4 is for a variant that is found in a patient with a phenotype that is known to be caused by the gene. However, the patient's phenotype isn't provided, so I can't confirm PS4. So PS criteria are not met.

PM1-6. PM1 is for a variant in a region of the gene that is known to be pathogenic. The position is c.6446, which is in the FBN1 gene. I need to check if this is in a known pathogenic region. FBN1 is associated with Marfan syndrome, and the gene has several exons. The exact location of c.6446 might be in a region that's not well-known for pathogenic variants, but without specific data, I can't confirm PM1. PM2 is for a variant that is in a region of the gene that is known to be pathogenic. Again, without specific information, this is unclear. PM3 is for a variant that is in a region that is highly conserved. The phyloP score is N/A, so I can't assess conservation. PM4 is for a variant that is predicted to affect protein function. The CADD and REVEL scores are 0.98 and 0.869, which are below the thresholds for strong evidence (CADD >20, REVEL >0.75). So PM4 might not be met. PM5 is for a variant that is in a gene where the variant is in a region that is known to be pathogenic. Again, without specific data, this is uncertain. PM6 is for a variant that is in a gene where the variant is in a region that is known to be pathogenic. Same as PM5. So PM criteria are not met.

PP1-5. PP1 is for a variant that is found in a patient with a phenotype that is known to be caused by the gene. Since the patient's phenotype isn't provided, I can't apply this. PP2 is for a variant that is in a gene where the variant is in a region that is known to be pathogenic. Again, without specific data, this is unclear. PP3 is for a variant that is predicted to affect protein function. The CADD and REVEL scores are low, so this might not apply. PP4 is for a variant that is found in a patient with a phenotype that is known to be caused by the gene. Same as PP1. PP5 is for a variant that is found in a patient with a phenotype that is known to be caused by the gene. Again, no phenotype data. So PP criteria are not met.

BA1 is for a variant that is in a gene where the variant is in a region that is known to be pathogenic. No data here. BS1-4. BS1 is for a variant that is found in a population database with a high frequency. The gnomAD AF is None, so this doesn't apply. BS2 is for a variant that is in a gene where the variant is in a region that is known to be pathogenic. Again, no data. BS3 is for a variant that is in a gene where the variant is in a region that is known to be pathogenic. Same as BS2. BS4 is for a variant that is in a gene where the variant is in a region that is known to be pathogenic. No data. BP1-7. BP1 is for a variant that is in a gene where the variant is in a region that is known to be pathogenic. No data. BP2 is for a variant that is in a gene where the variant is in a region that is known to be pathogenic. No data. BP3 is for a variant that is in a gene where the variant is in a region that is known to be pathogenic. No data. BP4 is for a variant that is in a gene where the variant is in a region that is known to be pathogenic. No data. BP5 is for a variant that is in a gene where the variant is in a region that is known to be pathogenic. No data. BP6 is for a variant that is in a gene where the variant is in a region that is known to be pathogenic. No data. BP7 is for a variant that is in a gene where the variant is in a region that is known to be pathogenic. No data.

Now, considering the ClinGen SVI recommendations for PS3/BS3 and PVS1. Since the variant is missense, PVS1 doesn't apply. For PS3, if there were functional studies, but they are N/A. So PS3 isn't met. BS3 would be if the variant is in a region that is not known to be pathogenic, but again, without data, I can't confirm that.

Putting it all together, there's no strong evidence for pathogenicity. The CADD and REVEL scores are low, and no population data, ClinVar, or functional studies. The variant is not in any known pathogenic regions. So the classification would likely be VUS (Variant of Uncertain Significance) with low confidence. However, since FBN1 is a known gene for Marfan syndrome, and the variant is in a missense position, but without any supporting evidence, it's hard to classify as pathogenic. The lack of data in all categories leads to VUS.
</think>

### ACMG/AMP 2015 기준에 따른 변이 해석

#### **1. PVS1 (Pathogenic Variant in a Gene with Loss-of-Function Disease Mechanism)**
- **결과**: **불충족**
- **근거**: 변이는 **missense** (p.Tyr2149Ser)로, **loss-of-function** 메커니즘을 유발하지 않습니다. PVS1은 **nonsense, frameshift, canonical splice site** 등 **loss-of-function** 유형의 변이에 적용되며, 본 변이는 해당 조건을 충족하지 않습니다.

---

#### **2. PS1-4 (Population and Phenotype-Based Evidence)**
- **PS1 (Known Pathogenic Variant in the Same Gene)**: **불충족**  
  - ClinVar 및 HGMD에 해당 변이가 등록되지 않음.
- **PS2 (Multiple Unrelated Individuals with Disease)**: **불충족**  
  - 가계 분리 및 환자-대조군 데이터 없음.
- **PS3 (Functional Studies Supporting Pathogenicity)**: **불충족**  
  - 기능 연구 데이터 (in vitro/in vivo) 없음.
- **PS4 (Phenotype Consistency with Disease)**: **불충족**  
  - 환자의 임상 증상 또는 유전자-증상 연관성 데이터 부재.

---

#### **3. PM1-6 (Sequence Conservation and Functional Prediction)**
- **PM1 (Known Pathogenic Region in the Gene)**: **불충족**  
  - FBN1 유전자의 **c.6446** 위치가 특정 pathogenic 영역인지에 대한 정보 부재.
- **PM2 (Known Pathogenic Region in the Gene)**: **불충족**  
  - 동일한 PM1 근거.
- **PM3 (High Conservation in the Region)**: **불충족**  
  - phyloP 보존성 데이터 없음.
- **PM4 (Predicted to Affect Protein Function)**: **불충족**  
  - CADD (0.98) 및 REVEL (0.869) 점수는 **pathogenicity 예측 기준 (CADD >20, REVEL >0.75)**을 충족하지 않음.
- **PM5 (Known Pathogenic Variant in the Same Amino Acid Position)**: **불충족**  
  - 동일한 아미노산 위치 (Tyr2149)의 pathogenic 변이 기록 없음.
- **PM6 (Known Pathogenic Variant in the Same Gene with Similar Amino Acid Change)**: **불충족**  
  - 유사한 아미노산 변화 (Serine)의 pathogenic 변이 기록 없음.

---

#### **4. PP1-5 (Phenotype and Population-Based Evidence)**
- **PP1 (Phenotype Consistency with Disease)**: **불충족**  
  - 환자의 임상 증상 데이터 부재.
- **PP2 (De Novo Mutation in a Disease Gene)**: **불충족**  
  - de novo 발생 여부 데이터 없음.
- **PP3 (Predicted to Affect Protein Function)**: **불충족**  
  - PM4와 동일한 근거.
- **PP4 (Phenotype Consistency with Disease)**: **불충족**  
  - PP1과 동일한 근거.
- **PP5 (Phenotype Consistency with Disease)**: **불충족**  
  - PP1과 동일한 근거.

---

#### **5. BA1 (Benign Allele in a Disease Gene)**: **불충족**  
- **근거**: BA1은 **benign** 변이에 대한 증거를 요구하지만, 본 변이는 **benign** 또는 **neutral** 유전자형을 지원하는 데이터가 없음.

---

#### **6. BS1-4 (Benign or Neutral Evidence)**
- **BS1 (High Frequency in Population Databases)**: **불충족**  
  - gnomAD AF (전체/인종별) 데이터 없음.
- **BS2 (Known Benign Variant in the Same Gene)**: **불충족**  
  - ClinVar 및 HGMD에 benign 변이 기록 없음.
- **BS3 (Not in a Known Pathogenic Region)**: **불충족**  
  - FBN1 유전자의 **c.6446** 위치가 pathogenic 영역인지에 대한 정보 부재.
- **BS4 (Predicted to Be Benign)**: **불충족**  
  - CADD 및 REVEL 점수가 **benign** 예측 기준 (CADD <10, REVEL <0.5)을 충족하지 않음.

---

#### **7. BP1-7 (Benign or Neutral Evidence)**
- **BP1 (Known Benign Variant in the Same Gene)**: **불충족**  
  - BS2와 동일한 근거.
- **BP2 (Known Benign Variant in the Same Amino Acid Position)**: **불충족**  
  - BS3와 동일한 근거.
- **BP3 (Known Benign Variant in the Same Gene with Similar Amino Acid Change)**: **불충족**  
  - BS4와 동일한 근거.
- **BP4 (Known Benign Variant in the Same Gene with Similar Amino Acid Change)**: **불충족**  
  - 동일한 근거.
- **BP5 (Known Benign Variant in the Same Gene with Similar Amino Acid Change)**: **불충족**  
  - 동일한 근거.
- **BP6 (Known Benign Variant in the Same Gene with Similar Amino Acid Change)**: **불충족**  
  - 동일한 근거.
- **BP7 (Known Benign Variant in the Same Gene with Similar Amino Acid Change)**: **불충족**  
  - 동일한 근거.

---

### **ClinGen SVI 권고안 적용**
- **PS3/BS3 강도 조절**:  
  - PS3 (기능 연구) 및 BS3 (비경로 영역)에 대한 증거 부족으로, **PS3/BS3** 기준 적용 불가.
- **PVS1 강도 조절**:  
  - PVS1은 missense 변이에 적용되지 않음.

---

### **최종 분류**
- **분류**: **VUS (Variant of Uncertain Significance)**  
- **신뢰도**: **낮음**  
- **임상적 해석**:  
  - FBN1 유전자는 Marfan syndrome과 관련된 것으로 알려져 있으나, 본 변이 (p.Tyr2149Ser)는 **missense** 유형이며, **CADD/REVEL 점수**가 pathogenicity 예측 기준을 충족하지 않음.  
  - **gnomAD**, **ClinVar**, **HGMD**, **기능 연구** 등 모든 증거 데이터가 부재하여, **병원성 또는 무해성**을 판단할 수 없음.  
  - 추가적인 **가계 분리 분석**, **기능 연구**, 또는 **임상 증상 데이터**가 필요함.

---

### **요약**
- **ACMG/AMP 기준**: **PVS1-PS4, PM1-PM6, PP1-PP5, BA1, BS1-BS4, BP1-BP7** 모두 **불충족**.  
- **ClinGen SVI**: PS3/BS3, PVS1 강도 조절 적용 불가.  
- **최종 분류**: **VUS (Low Confidence)**.